ANI Pharmaceuticals (NASDAQ:ANIP) Stock Crosses Above Fifty Day Moving Average – Time to Sell?

02 Jul 2026, 00:21 by Kim Johansen · The Markets Daily

Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP – Get Free Report) crossed above its fifty day moving average during trading on Monday . The stock has a fifty day moving average of $80.70 and traded as high as $85.25. ANI Pharmaceuticals shares last traded at $84.11, with a volume of 315,574 shares.

Analyst Ratings Changes

A number of research firms have recently weighed in on ANIP. Weiss Ratings raised ANI Pharmaceuticals from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Tuesday, June 23rd. Zacks Research cut ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Thursday, May 14th. Finally, Wall Street Zen upgraded ANI Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Saturday, May 9th. Six analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $107.33.

Check Out Our Latest Stock Report on ANIP

ANI Pharmaceuticals Price Performance

The firm has a market cap of $1.89 billion, a PE ratio of 21.03 and a beta of 0.44. The stock has a 50 day simple moving average of $80.77 and a two-hundred day simple moving average of $79.35. The company has a debt-to-equity ratio of 1.06, a quick ratio of 2.52 and a current ratio of 3.12.

ANI Pharmaceuticals (NASDAQ:ANIP – Get Free Report) last issued its quarterly earnings data on Friday, May 8th. The specialty pharmaceutical company reported $2.05 earnings per share for the quarter, topping analysts’ consensus estimates of $1.28 by $0.77. ANI Pharmaceuticals had a net margin of 9.98% and a return on equity of 27.51%. The business had revenue of $237.46 million during the quarter, compared to the consensus estimate of $207.63 million. During the same quarter in the prior year, the firm posted $1.70 earnings per share. The company’s revenue was up 20.5% compared to the same quarter last year. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. Sell-side analysts expect that ANI Pharmaceuticals, Inc. will post 8.03 earnings per share for the current year.

Insiders Place Their Bets

In related news, Director Patrick D. Walsh sold 10,000 shares of the company’s stock in a transaction dated Wednesday, May 13th. The shares were sold at an average price of $80.63, for a total transaction of $806,300.00. Following the completion of the transaction, the director owned 38,432 shares in the company, valued at $3,098,772.16. This represents a 20.65% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Thomas Haughey sold 2,000 shares of the firm’s stock in a transaction dated Monday, June 8th. The shares were sold at an average price of $80.88, for a total transaction of $161,760.00. Following the completion of the transaction, the director directly owned 38,878 shares in the company, valued at $3,144,452.64. This represents a 4.89% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 81,866 shares of company stock valued at $6,435,733. 8.10% of the stock is owned by company insiders.

Hedge Funds Weigh In On ANI Pharmaceuticals

A number of hedge funds have recently made changes to their positions in ANIP. Pacer Advisors Inc. lifted its position in shares of ANI Pharmaceuticals by 6.9% in the first quarter. Pacer Advisors Inc. now owns 85,467 shares of the specialty pharmaceutical company’s stock valued at $6,572,000 after acquiring an additional 5,548 shares in the last quarter. Bank of America Corp DE increased its position in shares of ANI Pharmaceuticals by 229.4% during the first quarter. Bank of America Corp DE now owns 150,532 shares of the specialty pharmaceutical company’s stock worth $11,576,000 after purchasing an additional 104,828 shares in the last quarter. Janus Henderson Group PLC raised its stake in ANI Pharmaceuticals by 1,308.1% in the 1st quarter. Janus Henderson Group PLC now owns 109,552 shares of the specialty pharmaceutical company’s stock valued at $8,425,000 after purchasing an additional 101,772 shares during the last quarter. California State Teachers Retirement System raised its stake in ANI Pharmaceuticals by 57.3% in the 1st quarter. California State Teachers Retirement System now owns 24,557 shares of the specialty pharmaceutical company’s stock valued at $1,888,000 after purchasing an additional 8,946 shares during the last quarter. Finally, The Manufacturers Life Insurance Company lifted its holdings in ANI Pharmaceuticals by 1.5% in the 1st quarter. The Manufacturers Life Insurance Company now owns 9,577 shares of the specialty pharmaceutical company’s stock valued at $736,000 after purchasing an additional 143 shares in the last quarter. Institutional investors and hedge funds own 76.05% of the company’s stock.

About ANI Pharmaceuticals

(Get Free Report)

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.